DUBLIN--(

都柏林--(

BUSINESS WIRE

商业热线

)--The

)--The

'Minimal Residual Disease Testing Market Size, Share, Forecast, & Trends Analysis By Offering, Technology, Application Sample - Global Forecast to 2031'

'最小残留病检测市场规模、份额、预测和趋势分析（按产品、技术、应用样本）-2031年全球预测'

report has been added to

报告已添加到

ResearchAndMarkets.com's

ResearchAndMarkets.com的

offering.

提供。

The minimal residual disease testing market is forecast to reach $4.45 billion by 2031, at a CAGR of 14.6% during the forecast period 2024-2031.

预计到2031年，最小残留病检测市场将达到44.5亿美元，2024-2031年的复合年增长率为14.6%。

Minimal Residual Disease (MRD) testing is crucial for cancer-affected patients. MRD tests provide early insights into whether a treated cancer patient is at risk of relapse or cancer recurrence. Early information helps physicians make treatment decisions depending on the cancer type and recurrence rates, which may lead to improved patient outcomes and better quality of life.

最小残留病（MRD）检测对于受癌症影响的患者至关重要。MRD测试可以早期了解接受治疗的癌症患者是否有复发或癌症复发的风险。早期信息有助于医生根据癌症类型和复发率做出治疗决策，这可能会改善患者的预后和更好的生活质量。

Additionally, MRD testing is being increasingly used in clinical trials by pharmaceutical and biopharmaceutical companies focused on the development of cancer therapies. These are some of the major factors driving the adoption of MRD testing globally..

此外，专注于癌症治疗开发的制药和生物制药公司越来越多地将MRD测试用于临床试验。这些是推动全球采用MRD测试的一些主要因素。。

The growth of the minimal residual disease testing market is driven by the growing incidence of cancer, the increasing application of MRD in hematological malignancies, the high recurrence rates of some cancers, and increasing investments and funding for MRD testing. Moreover, emerging economies, the rising adoption of personalized treatments & targeted therapies in the field of oncology, and the growing use of MRD testing in cases of solid tumors are expected to generate market growth opportunities..

微小残留病检测市场的增长是由癌症发病率的增加，MRD在血液系统恶性肿瘤中的应用增加，某些癌症的高复发率以及MRD检测的投资和资金增加所驱动的。此外，新兴经济体、肿瘤学领域越来越多地采用个性化治疗和靶向治疗以及在实体瘤病例中越来越多地使用MRD检测，预计将产生市场增长机会。。

Rising Adoption of Personalized Treatments & Targeted Therapies in the Field of Oncology

肿瘤学领域越来越多地采用个性化治疗和靶向治疗

As researchers are able to identify the unique genetic profiles of tumors, MRD testing is gaining traction in personalized oncology medicine. By identifying residual cancer cells in a patient, physicians can make decisions about the intensity of the treatments or tailor treatments based on the individual's response to treatments.

随着研究人员能够识别肿瘤的独特遗传特征，MRD测试在个性化肿瘤医学中越来越受欢迎。通过识别患者体内残留的癌细胞，医生可以根据患者对治疗的反应来决定治疗的强度或定制治疗。

MRD testing goes hand in hand with personalized medicine to improve therapeutic efficacy and make patient management more precise..

MRD测试与个性化医疗齐头并进，以提高治疗效果并使患者管理更加精确。。

The integration of MRD testing into clinical pathways supports the validation of targeted therapies. As new drugs are being developed to target specific genetic mutations, MRD testing can provide valuable insights into treatment effectiveness. For instance, in 2023, the U.S. FDA approved 16 personalized treatments for rare diseases, of which seven were for cancer.

将MRD测试整合到临床路径中支持靶向治疗的验证。随着针对特定基因突变的新药的开发，MRD检测可以为治疗效果提供有价值的见解。例如，2023年，美国FDA批准了16种罕见疾病的个性化治疗方法，其中7种用于癌症。

Combining targeted therapies and MRD testing can facilitate early intervention strategies, potentially preventing relapse and improving long-term outcomes for patients. Thus, the shift toward personalized treatments and targeted therapies in oncology is expected to generate growth opportunities for the players operating in the Minimal Residual Disease (MRD) testing market..

结合靶向治疗和MRD检测可以促进早期干预策略，有可能预防复发并改善患者的长期预后。因此，肿瘤学向个性化治疗和靶向治疗的转变有望为在最小残留病（MRD）检测市场上运营的参与者带来增长机会。。

Minimal Residual Disease Testing Market: Future Outlook

微小残留病检测市场：未来展望

Among the offerings studied in this report, in 2024, the assays & reagents segment is expected to account for the largest share of 76.7% of the minimal residual disease testing market. The recurrent use of assays & reagents, increasing research & development in the field of oncology leading to the emergence of new MRD tests, market players' focus on introducing new assays for minimal residual disease testing, and the rising adoption of MRD testing in clinical trials, contribute to the substantial market share of this segment..

在本报告研究的产品中，预计2024年，检测和试剂部门将占最小残留病检测市场的76.7%的最大份额。检测和试剂的反复使用，肿瘤学领域的研究和开发不断增加，导致新的MRD检测的出现，市场参与者专注于引入新的最小残留疾病检测方法，以及临床试验中MRD检测的不断采用，为该细分市场的巨大市场份额做出了贡献。。

Among the technologies studied in this report, in 2024, the flow cytometry segment is expected to account for the largest share of 42.7% of the minimal residual disease testing market. This segment's significant market share is attributed to the technology's ability to provide real-time, quantitative data on the number and type of cancer cells in a sample, the widespread availability of flow cytometers, and the relatively lower costs of flow cytometry consumables compared to more advanced technologies such as Next-generation Sequencing (NGS)..

。这一细分市场的巨大市场份额归因于该技术能够提供样本中癌细胞数量和类型的实时定量数据，流式细胞仪的广泛可用性，以及与更先进的技术（如下一代测序（NGS））相比，流式细胞仪耗材的成本相对较低。。

Among the applications studied in this report, in 2024, the blood cancers segment is expected to account for the larger share of the minimal residual disease testing market. The segment's large share is attributed to the growing incidence of blood cancers, the advent of new diagnostic technologies, the rising focus on precision oncology, high investments in MRD testing for blood cancers, and the wide availability of MRD testing solutions for blood cancers..

在本报告研究的应用中，预计2024年，血癌部分将在最小残留病检测市场中占据更大份额。该部门的巨大份额归因于血癌发病率的增长，新诊断技术的出现，对精确肿瘤学的日益关注，对血癌MRD检测的高投资以及血癌MRD检测解决方案的广泛可用性。。

Among the sample types studied in this report, in 2024, the blood segment is expected to account for the largest share of the minimal residual disease testing market. This segment holds a large market share due to the growing cancer incidence, the noninvasiveness of procedures used to obtain blood samples, and better patient compliance in the case of regular blood-based MRD monitoring..

在本报告研究的样本类型中，预计到2024年，血液部分将占最小残留病检测市场的最大份额。由于癌症发病率的增长，用于获取血液样本的程序的无创性，以及在定期基于血液的MRD监测的情况下更好的患者依从性，该细分市场占有很大的市场份额。。

Among the customer types studied in this report, in 2024, the pharmaceutical & biopharmaceutical companies segment is expected to account for the largest share of the minimal residual disease testing market. This segment's large market share is attributed to the high adoption of MRD testing in clinical trials for oncology therapies, high investments in oncology drug development and research, and supportive initiatives by regulatory authorities to promote MRD testing in drug trials..

在本报告研究的客户类型中，预计2024年，制药和生物制药公司部门将在最小残留病检测市场中占据最大份额。这一细分市场的巨大市场份额归因于在肿瘤治疗的临床试验中高度采用MRD测试，在肿瘤药物开发和研究中的高投资，以及监管机构促进药物试验中MRD测试的支持举措。。

Among the geographies studied in this report, in 2024, APAC is estimated to register the highest CAGR during the forecast period. Asia-Pacific is becoming an increasingly active market for healthcare product manufacturers and service providers due to improving healthcare infrastructure in the region.

在本报告研究的地区中，预计2024年亚太地区的复合年增长率将达到预测期内的最高水平。由于该地区医疗基础设施的改善，亚太地区正成为医疗保健产品制造商和服务提供商日益活跃的市场。

Asia-Pacific's growing population is the key factor driving the region's healthcare sector..

亚太地区不断增长的人口是推动该地区医疗保健部门发展的关键因素。。

This growth is attracting investments from private and public organizations in the development of MRD testing solutions. The rising incidence of cancer, improving healthcare infrastructure, the growing focus on personalized therapies, increasing cancer screening initiatives, and the availability of funding for cancer research are driving market growth in Asia-Pacific..

这种增长正在吸引私人和公共组织对MRD测试解决方案开发的投资。癌症发病率的上升、医疗保健基础设施的改善、对个性化治疗的日益关注、癌症筛查计划的增加以及癌症研究资金的可用性正在推动亚太地区的市场增长。。

Some of the major players studied in this report are

本报告研究的一些主要参与者是

Natera Inc.

Natera公司。

Bio-Rad Laboratories, Inc.

Bio-Rad实验室公司。

F. Hoffmann-La Roche Ltd.

F、 霍夫曼罗氏有限公司。

Adaptive Biotechnologies Corporation

自适应生物技术公司

Illumina, Inc.

Illumina公司。

Thermo Fisher Scientific, Inc.

赛默飞世尔科技有限公司。

Qiagen N.V.

Qiagen N.V。

Integrated DNA Technologies, Inc. (U.S.) (A Subsidiary of Danaher Corporation [U.S.])

Integrated DNA Technologies，Inc.（美国）（Danaher Corporation[美国]的子公司）

Twist Bioscience Corporation

Twist生物科学公司

Sysmex Corporation

Sysmex公司

Invivoscribe, Inc.

Invivoscribe，股份有限公司。

Key Topics Covered:

涵盖的关键主题：

1. Introduction

1、简介

2. Research Methodology

2、研究方法

3. Executive Summary

3、执行摘要

4. Market Insights

4、市场洞察

4.1. Overview

4.1条。概述

4.2. Factors Affecting Market Growth

四点二。影响市场增长的因素

4.2.1. Drivers

4.2.1。驱动程序

4.2.1.1. Growing Incidence of Cancer

4.2.1.1。癌症发病率不断上升

4.2.1.2. Increasing Investments & Funding for MRD Testing & Research

4.2.1.2。

4.2.2. Restraints

4.2.2。约束

4.2.2.1. High Costs of Minimal Residual Disease Testing

4.2.2.1。微小残留病检测的高成本

4.2.3. Opportunities

4.2.3。机会

4.2.3.1. Rising Adoption of Personalized Treatments & Targeted Therapies In the Field of Oncology

4.2.3.1。肿瘤学领域越来越多地采用个性化治疗和靶向治疗

4.2.3.2. Growing Use of MRD Testing In Cases of Solid Tumors

4.2.3.2。在实体瘤病例中越来越多地使用MRD检测

4.2.4. Challenges

4.2.4。挑战

4.2.4.1. Chances of False Positive/Negative Results

4.2.4.1。假阳性/阴性结果的可能性

4.2.5. Trends

4.2.5。趋势

4.2.5.1. Emergence of Digital PCR

4.2.5.1。数字PCR的出现

4.2.5.2. Use of Mass Spectrometry for MRD Testing

4.2.5.2。质谱法在MRD检测中的应用

4.2.5.3. Integration of Single-Cell Multiomics & Artificial Intelligence Into Minimal Residual Disease Testing

4.2.5.3。将单细胞多组学和人工智能整合到最小残留病检测中

4.2.6. Factors Analysis

4.2.6。因素分析

4.3. Regulatory Analysis

四点三。监管分析

4.4. Porter's Five Forces Analysis

四点四。五力分析

4.5. Technology Evolution Roadmap

四点五。技术发展路线图

5. Minimal Residual Disease Testing Market Assessment - By Offering

最小残留病检测市场评估-通过提供

5.1. Overview

5.1条。概述

5.2. Assays & Reagents

五点二。分析和试剂

5.3. Instruments

五点三。仪器

5.4. Software & Services

五点四。软件和服务

6. Minimal Residual Disease Testing Market Assessment - By Technology

6.1. Overview

六点一。概述

6.2. Flow Cytometry

六点二。流式细胞术

6.3. Polymerase Chain Reaction

六点三。聚合酶链式反应

6.4. Next-Generation Sequencing

六点四。下一代测序

6.5. Other Technologies

六点五。其他技术

7. Minimal Residual Disease Testing Market Assessment - By Application

最小残留病检测市场评估-按应用

7.1. Overview

7.1条。概述

7.2. Blood Cancers

七点二。血癌

7.2.1. Lymphoma

7.2.1。淋巴瘤

7.2.2. Leukemia

7.2.2。

7.2.2.1. Acute Lymphoblastic Leukemia (ALL)

7.2.2.1。急性淋巴细胞白血病（ALL）

7.2.2.2. Chronic Lymphocytic Leukemia (CLL)

7.2.2.2。慢性淋巴细胞白血病（CLL）

7.2.2.3. Other Leukemias

7.2.2.3。其他白血病

7.2.3. Multiple Myeloma

7.2.3。多发性骨髓瘤

7.2.4. Other Blood Cancers

7.2.4。其他血癌

7.3. Solid Tumors

七点三。实体瘤

8. Minimal Residual Disease Testing Market Assessment - By Sample Type

8、最小残留病检测市场评估——按样本类型

8.1. Overview

8.1条。概述

8.2. Blood

八点二。血液

8.3. Bone Marrow

八点三。骨髓

8.4. Other Sample Types

八点四。其他样本类型

9. Minimal Residual Disease Testing Market Assessment - By Customer Type

最小残留病检测市场评估-按客户类型

9.1. Overview

9.1条。概述

9.2. Pharmaceutical & Biopharmaceutical Companies

九点二。制药和生物制药公司

9.3. Hospitals

九点三。医院

9.4. Diagnostic Laboratories

。诊断实验室

9.5. Academic & Research Organizations/Institutions

九点五。学术和研究组织/机构

10. Minimal Residual Disease Testing Market Assessment - By Geography

最小残留病检测市场评估-按地理位置

10.1. Overview

10.1条。概述

10.2. North America

10.2条。北美

10.3. Europe

10.3条。欧洲

10.4. Asia-Pacific

10.4条。亚太地区

10.5. Latin America

10.5条。拉丁美洲

11. Competitive Landscape

11、竞争格局

11.1. Overview

11.1条。概述

11.2. Key Growth Strategies

11.2条。关键增长战略

11.3. Competitive Benchmarking

11.3条。竞争基准

11.4. Competitive Dashboard

。竞争仪表板

11.5. Market Share Analysis (2023)

11.5条。市场份额分析（2023年）

Natera Inc. (U.S.)

Natera Inc.（美国）

Bio-Rad Laboratories, Inc. (U.S.)

Bio-Rad实验室，股份有限公司（美国）

F. Hoffmann-La Roche Ltd. (Switzerland)

F.Hoffman-La Roche有限公司（瑞士）

Adaptive Biotechnologies Corporation (U.S.)

自适应生物技术公司（美国）

For more information about this report visit

有关此报告的更多信息，请访问

https://www.researchandmarkets.com/r/fl1p2p

https://www.researchandmarkets.com/r/fl1p2p

About ResearchAndMarkets.com

关于ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

。我们为您提供有关国际和地区市场、关键行业、顶尖公司、新产品和最新趋势的最新数据。